178 related articles for article (PubMed ID: 36793588)
1. Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma.
Bian Y; Bi G; Shan G; Liang J; Sui Q; Hu Z; Wang Q; Zhang Y; Fan H
J Immunol Res; 2023; 2023():4987832. PubMed ID: 36793588
[TBL] [Abstract][Full Text] [Related]
2. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
Dai D; Shi R; Han S; Jin H; Wang X
Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
[TBL] [Abstract][Full Text] [Related]
3. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
Dodin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
[TBL] [Abstract][Full Text] [Related]
4. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
5. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
Li HS; Liu CM; Wang Y
Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
[TBL] [Abstract][Full Text] [Related]
6. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract][Full Text] [Related]
7. Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma.
Peng X; Xia Z; Guo Y; Li Y
Aging (Albany NY); 2023 Jun; 15(11):4889-4905. PubMed ID: 37279937
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
10. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
11. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
12. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
Li F; Ge D; Sun SL
BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
[TBL] [Abstract][Full Text] [Related]
13.
Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
[No Abstract] [Full Text] [Related]
14. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
15. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
17. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
18. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
20. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
